By Jason Derry --
In May 2006, XOMA Ltd. and Schering-Plough Corp. agreed to a collaboration relating to discovery and development of therapeutic monoclonal antibodies. Under the agreement, Schering-Plough selects the targets and XOMA uses its proprietary antibody technology to discover antibodies of therapeutic interest. On Wednesday, XOMA announced that Schering-Plough exercised its option for additional discovery and development programs.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments